SiPhox Health, a company based in Burlington, MA, has secured $27 million in funding for its innovative lab-grade home health testing system, which utilises silicon photonics technology. The funding includes a $10 million Seed round led by Khosla Ventures and Y Combinator, as well as a $17 million Series A round led by Intel Capital.
SiPhox Health's Home and Health testing systems aim to provide efficient and convenient blood collection solutions for consumers, healthcare systems, pharmaceutical companies, and research teams focused on longevity and chronic disease management. The current state of chronic diseases affecting 6 out of 10 Americans underscores the need for low-cost, accessible testing options that can help prevent and manage these conditions. Traditional tests can be expensive, time-consuming, and burdensome, making SiPhox's approach particularly promising.
The company's mail-in blood collection kit measures 17 biomarkers related to inflammation, metabolic health, hormonal health, and cardiovascular health. Their goal is to make individualised testing easily accessible on a large scale, and they plan to obtain FDA clearance for their SiPhox Home platform, which will offer a broader menu of protein and hormone tests. The results from these tests can be obtained in five minutes or less from a simple finger prick blood sample.
SiPhox Health aims to create groundbreaking health-tracking products, starting with SiPhox Home, which is claimed to be a significant improvement over existing blood diagnostics. The company envisions a future where its technology will enable the development of the ultimate wearable device for the continuous measurement of proteins, hormones, and small molecules.
Click here to read the original news story.